Apollomics Inc (APLM) - News Archive

In a recent operational update issued on October 13, 2025, Apollomics, Inc. (Nasdaq: APLM) provided insights into its current corporate standing amidst fluctuating market conditions. The announcement, while affirming th...

Navigating the Complex Landscape of Relapsed Acute Myeloid Leukemia and MET-Fusion Solid Tumors: Insights from Apollomics’ Latest Trials In the realm of oncology, the quest for effective treatments for particularly chal...

Apollomics Announces Reverse Share Split: A Strategic Move ForwardOn September 16, 2024, Apollomics, a company pioneering advancements in the field of oncology, made an important announcement concerning its capital stru...

In this esteemed publication, we take the liberty of presenting findings that emanated from a notable assembly, the European Society for Medical Oncology (ESMO) Congress of the year 2024, where Apollomics revealed signi...

Apollomics, a biopharmaceutical company, recently unveiled its updated strategic focus, emphasizing the enrollment of non-small cell lung cancer (NSCLC) patients with Met Amplification mutations in the vebreltinib study...

In recent years, precision medicine has revolutionized cancer treatment by targeting specific genetic alterations within tumors. Apollomics, a leading biopharmaceutical company, has taken a significant step forward in t...

Apollomics Secures $6 Million in Private Placement Financing, Bolsters Board of DirectorsIn a move to further advance its mission of developing innovative oncology therapies, Apollomics Inc. has announced a successful p...

Apollomics Vebreltinib Granted Approval in China as Breakthrough Treatment for Gliomas with MET Fusion GeneApollomics, a leading biopharmaceutical company committed to the discovery and development of novel oncology tre...

In recent years, the field of oncology has witnessed remarkable advancements in the understanding of cancer biology and the development of targeted therapies. The 2024 American Association for Cancer Research (AACR) Ann...

Apollomics Inc. Successfully Enrolls Chinese Patients in Phase 3 Bridging Study of Uproleselan for Relapsed/Refractory Acute Myeloid LeukemiaInsert Date - Apollomics Inc., a renowned biopharmaceutical company dedicated...